No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma

Anti-Cancer Drugs

Volumn 17, Issue 4, 2006, Pages 411-415

  Bacci, Gaetano ^a,d   Loro, Loretta ^a   Longhi, Alessandra ^a   Bertoni, Franco ^b   Bacchini, Patrizia ^b   Versari, Michela ^a   Picci, Piero ^c   Serra, Massimo ^c  

^a Chemotherapy   (Italy)

^b Pathology   (Italy)

^c Laboratory of Oncologic Research   (Italy)

^d RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Chemotherapy; Histologic response; Methotrexate; Osteosarcoma

Indexed keywords

CISPLATIN; DOXORUBICIN; FOLINIC ACID; METHOTREXATE;

ADOLESCENT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PROTOCOL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIMB; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR NECROSIS; VARIANCE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; EXTREMITIES; FEMALE; HUMANS; MALE; METHOTREXATE; NEOADJUVANT THERAPY; OSTEOSARCOMA; PREOPERATIVE CARE;

EID: 33748194237     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000203379.14738.d9     Document Type: Article

References (17)

1. Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos AG. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979; 43:2163-2177.
2. Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, Beck W, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J Clin Oncol 1984; 2:617-624.
3. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986; 314:1600-1606.
4. Saeter G, Alvegard TA, Elomaa I, Stenwig AE, Holmstrom T, Solheim OP. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol 1991; 9:1766-1775.
5. Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992; 10:5-15.
6. Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 1997; 15:76-84.
7. Bacci G, Mercuri M, Longhi A, Ferrari S, Bertoni F, Versari M, et al. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Eur J Cancer 2005; 41:2079-2085.
8. Delepine N, Delepine G, Cornille H, Brion F, Arnaud P, Desbois JC. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma. Anticancer Res 1995; 15:489-494.
9. Graf N, Winkler K, Betlemovic M, Fuchs N, Bode U. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 1994; 12:1443-1451.
10. Zelcer S, Kellick M, Wexler LH, Shi W, Sankaran M, Lo S, et al. Methotrexate levels and outcome in osteosarcoma. Pediatr Blood Cancer 2005; 44:638-642.
11. Bacci G, Picci P, Ruggieri P, Mercuri M, Avella M, Capanna R, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer 1990; 65:2539-2553.
12. Bacci G, Picci P, Ferrari S, Ruggieri P, Casadei R, Tienghi A, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 1993; 72:3227-3238.
13. Rosen G, Nirenberg A. Chemotherapy for osteogenic sarcoma: an investigative method, not a recipe. Cancer Treat Rep 1982; 66:1687-1697.
14. Picci P, Bacci G, Campanacci M, Gasparini M, Pilotti S, Cerasoli S, et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer 1985; 56:1515-1521.
15. Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 1977; 101:14-18.
16. Bacci G, Ferrari S, Delepine N, Bertoni F, Picci P, Mercuri M, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol 1998; 16:658-663.
17. Crom WR, Pratt CB, Green AA, Champion JE, Crom DB, Stewart CF, et al. The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexate. J Clin Oncol 1984; 2:655-661.